AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04336761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal swab
Description: Data collection and nasopharyngeal swab
Study NCT03252483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled HCV/HIV Screening
Description: Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
Study NCT03252483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Screening
Description: Participants were randomized to an HIV-only screening group as a control comparator.
Study NCT01459250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178C
Study NCT02061865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3
Study NCT02308683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera
Description: 12 weeks supplementation
Study NCT01524354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anesthesia
Description: intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
Study NCT01524354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anesthesia
Description: intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
Study NCT03441178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENSEAL X1
Description: ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
Study NCT01918670 — intervention group
Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection
Study NCT01353742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100mg tablet
Study NCT01353742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg tablet
Study NCT01353742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination (Lamivudine and Adefovir dipivoxil)
Description: 100mg/10mg capsule
Study NCT00968851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124
Description: Arms: 1
Study NCT00968851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm: 3
Study NCT00968851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124
Description: Arms: 2
Study NCT02937714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School Mental Health training
Description: School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
Study NCT01479712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Irrigation
Description: Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
Study NCT01056146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Interacting Together Everyday: Recovery After Childhood TBI
Description: Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
Study NCT01056146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Resources Comparison
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
Study NCT03743636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
Study NCT00654862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa polyphenols
Description: Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
Study NCT02670135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan Containing Toothpaste
Description: Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
Study NCT03743636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
Study NCT03743636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
Study NCT03743636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
Study NCT02670135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triclosan Free Toothpaste
Description: Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
Study NCT01283165 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health education intervention
Description: Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
Study NCT02386150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
Study NCT00986700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: late night meal
Description: Three different kinds of late night meal each for 2 days.
Study NCT02312492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oleic Diet
Description: The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
Study NCT02312492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmitic Diet
Description: The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
Study NCT02312492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stearic Diet
Description: The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
Study NCT02294240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy dense biscuits
Description: Energy dense biscuits will be provided
Study NCT02294240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Flour, oil, iron & Folic acid
Description: Wheat flour, oil, iron and folic acid will be provided
Study NCT01897636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle injection of DCs vaccinations
Study NCT00546052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
Study NCT00544609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
Study NCT00544609 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiotherapy
Description: 3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
Study NCT02305862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: drug intervention
Study NCT02305862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: drug intervention
Study NCT04589104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth
Study NCT02435355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based counselling
Description: The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
Study NCT04103801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
Study NCT04103801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
Study NCT04348409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide Tablets
Description: Patients will receive nitazoxanide 600 mg BID for 7 days
Study NCT04348409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo BID for 7 days
Study NCT05683444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide infusion
Description: Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
Study NCT05683444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline infusion
Description: Saline Infusion
Study NCT00398463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
Study NCT00398463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion will be administered for 14-24 hours
Study NCT03837080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
Study NCT00004001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00004001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine
Study NCT00004001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Study NCT00004001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT03285997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A
Description: A single 0.5mL dose intramuscular injection
Study NCT03285997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Pre-filled syringe inj.
Description: A single 0.25mL dose intramuscular injection
Study NCT00862264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Description: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Study NCT00862264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Description: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
Study NCT01625754 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
Study NCT01060358 — intervention group
Intervention type: PROCEDURE
Intervention: method (non-surgical) to measure neuromuscular neutral zones
Study NCT02586792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.
Study NCT05033496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function test
Description: Thyroid function test
Study NCT04693962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasmatic Fibroblast Growth Factor-23 by means of ELISA
Description: Plasma levels of FGF-23 will be measured by ELISA
Study NCT01877083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Starting dose of 24 mg orally, once per day
Study NCT02488122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Impact Exercise
Description: In these workouts, both feet leave the ground at the same time.
Study NCT02488122 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low Impact Exercise
Description: A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
Study NCT04320407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia 2 System
Description: The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
Study NCT01302808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (8 mg/m^2)
Study NCT01302808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (10 mg/m^2)
Study NCT01302808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
Study NCT01302808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis
Study NCT05122234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of secretome - mesenchymal stem cell
Description: Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
Study NCT05122234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT05122234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment of Covid-19
Description: Standard treatment of Covid-19 based on national protocol.
Study NCT05122234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment of Covid-19
Description: Standard treatment of Covid-19 based on national protocol.
Study NCT02613728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Recovery Plan
Study NCT02613728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Discharge
Study NCT02613728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Study NCT02613728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enhanced Care
Study NCT02161679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-132 infusion is administered to participants in one arm for the study
Study NCT02161679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMMU-132 infusion is administered to participants in one arm for the study
Study NCT02161679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-132 plus Carboplatin infusion
Study NCT02161679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMMU-132 plus Carboplatin infusion
Study NCT03632421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT03632421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT00037609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 taken by mouth twice daily.
Study NCT00037609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exisulind
Description: 125 mg taken by mouth twice daily.